Towards Personalized Molecular Imaging
Towards Personalized Molecular Imaging
iMiGiNE® is part of the Medical Systems Division of PMB. The human-sized company was founded in 1998 and it specializes in the design and manufacture of complex mechanical assemblies for the Medical, Research and Industry fields.
PMB has developed a strong expertise on the brazing of dissimilar materials such as ceramic-metal or metal-metal, as well as on the design and manufacture of RF components. After several technological improvements made on the cyclotron Oscar (Oxford Instruments), PMB designed the cyclotron iMiTRACE.
iMiGiNE Project
The idea of creating iMiGiNE originated from a simple assessment: the variety and accessibility of radiopharmaceuticals we use for PET imaging today is limited. Therefore, the treatment offered for patients is also limited or even inadequate. We want to help medical centers and research facilities to break new ground in PET imaging, by providing them with various radiopharmaceuticals which can target different pathologies and enable a personalized diagnosis.
Project iMiGiNE was launched in 2013, with the French academic partner CEA – Atomic Energy Commission – and the industrial partner SigmaPhi (magnetic systems manufacturer). It is partially funded by Bpifrance, a governmental financial institution dedicated to supporting innovation in small and medium-sized enterprises.
In 2016, the automated PET radiopharmaceutical production system iMiGiNE was launched commercially as a global solution combining a cyclotron, a radiochemistry module and a quality control device.
History
- 2012: Launch of the Project
- 2016: 1st beam at ITP in Madrid
- 2017: 1st production of Fluor
- 2017: Delivery of the 1st cyclotron in Guadeloupe to CIMGUA
- 2017: Commercial launch of iMiGiNE
- 2018: 1st patient diagnosed at CIMGUA
- 2018: Installation of the iMiDEV prototype in London and partnership with King's College
- 2019: iMiDEV installation in Nancy and partnership with Nancyclotep
- 2020: iMiDEV installation in Stockholm and partnership with Karolinska Institutet
- 2020: 1st automated synthesis at the SHFJ
- 2020: Commissioning of the 1st iMiGiNE at the SHFJ in Orsay
- 2021: 1st beam with helium-free iMiTRACE
- 2023: LOI signature with Eckert & Ziegler and Pentixapharm